Whole-genome analysis informs breast cancer response to aromatase inhibitionMatthew J. Ellis, Mark A. Watson, Li Ding et al.|Nature|2012Cited by 1k
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast CancerRita Nanda, Laura J. Esserman, Minetta C. Liu et al.|JAMA Oncology|2020Cited by 707
Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—Results from ACRIN 6657/I-SPY TRIALNola M. Hylton, Mitchell D. Schnall, Jeffrey D. Blume et al.|Radiology|2012Cited by 487
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)Matthew J. Ellis, Kelly K. Hunt, Vera J. Suman et al.|Journal of Clinical Oncology|2017Cited by 411
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialLajos Pusztai, Laura J. Esserman, Christina Yau et al.|Cancer Cell|2021Cited by 330